Leveraging newly released data from recent trials, such as WGS-TP-II32 and PHEDRA12, this study aims to demonstrate the optimal HER2-targeting regimen for HR+/HER2 + BC by integrating both short-term and long-term outcomes. Here, ERBB2 is linked to breast cancer.